Changing Management of Hematological Malignancies With COVID-19: Statement and Recommendations of the Lebanese Society of Hematology and Blood Transfusion

Simple item page
dc.contributor.authorIbrahim, Ahmad O.
dc.contributor.authorNoun, Peter E.
dc.contributor.authorKhalil, Charbel
dc.contributor.authorTaher, Ali T.
dc.contributor.departmentInternal Medicine
dc.contributor.departmentDivision of Hematology Oncology
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:43:10Z
dc.date.available2025-01-24T11:43:10Z
dc.date.issued2021
dc.description.abstractCOVID-19 caused by SARS-Cov-2 is a devastating infection in patients with hematological malignancies. In 2018, the Lebanese Society of Hematology and Blood Transfusion (LSHBT) updated the guidelines for the management of hematological malignancies in Lebanon. In 2019, it was followed by a second update. Given the rapidly changing evidence and general situation for COVID-19, the LSHBT established some recommendations and suggestions for the management of the patients with hematological malignancies taking into account the Lebanese condition, economic situation, and the facts that SARS-Cov-2 infection has apparently been devastating. In this article we present recommendations and proposals to reduce or to manage SARS-Cov-2 infection in the patients with myeloid and lymphoid hematological malignancies. © Copyright © 2021 Ibrahim, Noun, Khalil and Taher.
dc.identifier.doihttps://doi.org/10.3389/fonc.2021.564383
dc.identifier.eid2-s2.0-85103331290
dc.identifier.urihttp://hdl.handle.net/10938/30221
dc.language.isoen
dc.publisherFrontiers Media S.A.
dc.relation.ispartofFrontiers in Oncology
dc.sourceScopus
dc.subjectHematological malignancies
dc.subjectLshbt
dc.subjectLymphoid
dc.subjectMyeloid
dc.subjectSars-cov-2 infection
dc.subjectAcute lymphoblastic leukemia
dc.subjectAcute myeloid leukemia
dc.subjectAllogeneic hematopoietic stem cell transplantation
dc.subjectArticle
dc.subjectAutologous stem cell transplantation
dc.subjectBurkitt lymphoma
dc.subjectCancer chemotherapy
dc.subjectCancer immunotherapy
dc.subjectCancer recurrence
dc.subjectChronic lymphatic leukemia
dc.subjectChronic myeloid leukemia
dc.subjectConsolidation chemotherapy
dc.subjectCoronavirus disease 2019
dc.subjectCovid-19 testing
dc.subjectCutaneous t cell lymphoma
dc.subjectDiffuse large b cell lymphoma
dc.subjectHealth care system
dc.subjectHematologic malignancy
dc.subjectHematopoietic stem cell transplantation
dc.subjectHodgkin disease
dc.subjectHuman
dc.subjectImmunosuppressive treatment
dc.subjectInduction chemotherapy
dc.subjectLymphoma
dc.subjectMaintenance therapy
dc.subjectMantle cell lymphoma
dc.subjectMultiple myeloma
dc.subjectMyelodysplastic syndrome
dc.subjectMyeloproliferative neoplasm
dc.subjectPatient care
dc.subjectPeripheral blood stem cell transplantation
dc.subjectPeripheral t cell lymphoma
dc.subjectPolymerase chain reaction
dc.subjectPrimary central nervous system lymphoma
dc.subjectPromyelocytic leukemia
dc.titleChanging Management of Hematological Malignancies With COVID-19: Statement and Recommendations of the Lebanese Society of Hematology and Blood Transfusion
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
2021-2677.pdf
Size:
307.36 KB
Format:
Adobe Portable Document Format
Download

Collections

Internal Medicine